CorMedix Inc.
CRMDCorMedix Inc. is a healthcare company focused on developing and commercializing medical therapies for the prevention and containment of infections in hospital settings, particularly through its flagship product, Neutrolin, a patented antimicrobial solution used in central venous catheters to reduce bloodstream infections.
Company News
CorMedix is experiencing strong commercial momentum with its DefenCath catheter lock solution, which has shown a 72% reduction in catheter-related bloodstream infections in real-world evidence studies. The company reported Q3 2025 net revenue of $104.3 million and raised full-year guidance to $390-410 million. DefenCath adoption is outpacing expe...
The American Kidney Fund hosted its third annual Patient Access Initiative Summit focusing on innovative kidney care technologies, AI applications, and addressing barriers to kidney disease prevention and treatment.
Several biotech companies reported significant developments, including Kraig Labs' breakthrough in spider silk production, Salarius Pharmaceuticals' public offering, Humacyte's Q3 progress, and CorMedix's record quarterly earnings.
CorMedix completed enrollment in a Phase III clinical trial for REZZAYO, a drug aimed at preventing fungal infections in patients undergoing blood and marrow transplantation. Topline results are expected in Q2 2026, with potential FDA approval for prophylaxis treatment.
CorMedix has successfully acquired Melinta Therapeutics for $300 million, expanding its commercial product portfolio with seven innovative drug products and raising financial guidance to $325-$350 million in pro forma 2025 revenues.
